New Life for Approved Trans-Pacific Partnership

Now that the US, Japan and 10 other Pacific Rim economies have reached agreement to strike the largest trade pact seen anywhere in a generation, it is up to President Barack Obama to convince Congress that the deal is in our best interests.

Just when it appeared that agreement among participants comprising the Trans-Pacific Partnership (TPP) would not be reached this year, spokesmen announced that recent discussion rounds in Atlanta produced consensus.

As reported in Logistics Management, shippers have been championing this deal even as it appeared “dead in the water” this past summer.

The National Association of Manufacturers (NAM) was especially bullish on this proposition:

“The TPP negotiations have long presented a lot of hope for manufacturers in the United States and the millions of jobs they impact,” said Linda Dempsey, NAM’s Vice President of International Economic Affairs.

“If done right, this agreement has the potential to boost U.S. manufacturing growth and global competitiveness.”

Now that the US, Japan and 10 other Pacific Rim economies have reached agreement to strike the largest trade pact seen anywhere in a generation, it is up to President Barack Obama to convince Congress that the deal is in our best interests.

Shippers here understand, however, that the TPP will create a new Pacific economic bloc with reduced trade barriers for products as diverse as food, textiles, and mega-data.

Furthermore, logistics managers will finally be able to benefit by adhering to common standards on labor and the environment thereby creating a more sustainable investment strategy for the Pacific Rim.

The Just-Completed Trans-Pacific Partnership Deal, Explained
Trade negotiators in Atlanta reached an agreement Monday that could affect everything from American exports of pharmaceuticals to New Zealand milk, Japanese rice, and Vietnamese textiles.

The deal, known at the Trans-Pacific Partnership, would more closely link the economies of 12 Pacific Rim nations and have sweeping global implications. President Obama has portrayed it as essential to cementing America’s relationships in Asia, but critics such as Sen. Elizabeth Warren (D-MA) have portrayed it as a giveaway to corporate interests and a threat to US sovereignty.

A historic trade opportunity to further boost America’s current $727 billion in export goods with 11 allies abroad
Crew of 42
Dollar amounts represent U.S. goods exports to respective TPP countries in 2014. Data provided by U.S. Census Bureau

Of all the issues under negotiation, the most contentious was legal protections for the pharmaceutical industry. American drug companies and their allies in the Obama administration have been pushing for new rules that would limit competition and boost drug prices. Other countries, with the support of public health groups, have pushed back, arguing that the measures would cost thousands of lives.

Ultimately, the negotiators split the difference. They agreed to language that would require some countries to expand the legal protections afforded to drug companies (and raise prices in those countries), but big drug companies got less than they wanted.

Now the action will move to Congress, which must approve the deal before it can take effect. We can expect the TPP to attract criticism from both ends of the political spectrum. Already, Vermont Sen. and presidential candidate Bernie Sanders (D-VT) has blasted the deal as a victory for “Wall Street and other big corporations,” while Sen. Orrin Hatch (R-UT) has complained that the drug protections in the bill “fall woefully short” of what the industry had requested. Obama faces a big challenge convincing critics on both sides that while the deal might not be perfect, it’s still better than no deal at all.

The TPP is a lot more than just a trade deal
The TPP is usually described as a trade deal, and it certainly will have important provisions related to trade. Negotiators have been considering liberalizing trade in cars and trucks, rice, dairy products, textiles, and a lot more.

But the agreement is also a lot more than a trade deal. It has more than two dozen chapters that cover everything from tariffs to the handling of international investment disputes. The reason these deals have gotten so complex is that people realized that they were a good vehicle for creating binding international agreements.

American negotiators - and, therefore, US interest groups - have had the most power in these negotiations

Modern trade deals include a dispute-settlement process that helps to ensure that countries keep the commitments they make under trade deals. If one country fails to keep its commitment, another country can file a complaint that’s heard by an impartial tribunal. If the complaining country prevails, it can impose retaliatory tariffs on the loser.

Download the Paper

Interest groups have realized that this same mechanism can be used to enforce agreements on topics that have little to do with trade. And so a wide variety of interest groups - from Hollywood and the pharmaceutical industry to labor and environmental groups - have lobbied to include rules they favored in trade agreements. And because the US is the world’s largest economy, American negotiators - and, therefore, US interest groups - have had the most power in these negotiations.

For example, at the behest of Hollywood and other US copyright holders, American negotiators have been pushing other countries to adopt our long copyright terms: the life of the author plus 70 years.

International investors have pushed for an investor-state dispute settlement process that allows private investors to challenge foreign government policies before an impartial arbitration panel - a process critics such as Sen. Warren describe as a threat to American sovereignty. Drug companies want other countries to provide the same robust legal protections for new drugs they enjoy in the United States.

At the same time, labor and environment groups have pushed the Obama administration to incorporate their priorities into the agreement. The Obama administration insists the president has done just that, but so far these changes haven’t gone far enough to convince these groups to endorse the agreement.

Drug protections were the biggest sticking point
Previous trade deals already required TPP member countries to provide a minimum level of patent protection for pharmaceuticals, but most countries didn’t provide protections as generous as those in the United States. Obama’s trade negotiators wanted to include language in the TPP requiring other countries to make their laws more like those in the United States.

The most controversial provision of all concerns a type of drugs called biologics. These drugs are produced by biological processes rather than being synthesized in a chemistry lab. Drug companies say that patents, which protect a specific chemical formula, do not always provide adequate protection for biologic drugs, because it’s often possible to find another compound that’s biologically equivalent even though it has a different chemical structure.

Even the Obama administration’s own budget wonks believe 12 years of protection is excessive

To prevent generic drug manufacturers from copying biologics and driving down their prices, big drug companies have used the regulatory process to limit competition. The Food and Drug Administration - and other regulatory agencies overseas - require drugmakers to prove that a drug is safe and effective before it can be introduced to the market. US law gives the creators of a drug exclusive rights to this data for a period of 12 years. Because clinical trials are expensive to perform, this effectively prevents generic drugmakers from creating competing drugs until the exclusivity period has expired.

Even the Obama administration’s own budget wonks believe 12 years of protection is excessive. They’ve proposed reducing the protection period to seven years, and estimated that increased generic drug competition would save Medicare and other federal health-care programs billions of dollars. At the same time, Obama’s trade negotiators have been pushing for language that would lock in 12 years of protection in the United States and require other countries - most of which offer shorter terms of five or eight years - to adopt the same 12 years of protection as the United States.

The full details of the compromise haven’t been released - and might not be for another month - but media reports indicate that the US dropped its demand for 12 years of protection and settled for requiring five to eight years of protection instead. That’s a significant concession for the United States, but it’s still a victory of sorts for the pharmaceutical industry, since it will bar countries that currently offer five to eight years of protection from reducing it later. It also sets a floor, but not a ceiling - the United States will continue to offer 12 years of protection, and US negotiators may push for more lavish protections in future trade deals.

What happens next: months of waiting
While the TPP member countries have reached the outline of a deal, media reports suggest that not every detail of the agreement has been fully fleshed out. The New York Times predicts that it will take about a month for these details to be worked out and for the final text of the deal to be made publicly available.

After that, it will take another three to four months for Congress to enact a deal. Under the “fast track” legislation authorizing Obama to negotiate the deal, the president must give Congress 90 days’ notice before signing the trade deal, and then another wait another 30 days before introducing legislation implementing it. This means that even in the best-case scenario, Congress won’t be able to vote on the controversial deal until early 2016. And it could be delayed by further wrangling, either among TPP member countries or within Congress.

Obama’s big challenge will be that the deal has something for everyone to hate. Drug company allies like Orrin Hatch are disappointed that US negotiators didn’t get the generous drug protections they’d sought - that will make them less excited about the deal. Meanwhile, public health groups believe eight years of protection is too long.

Nothing has happened in the past few months to mollify the TPP’s many critics - most of whom come from the political left. We can expect many labor unions, environmental groups, and other left-leaning advocacy groups to lobby against the agreement.

However, Obama also has a huge advantage: The Republican leadership has firmly supported Obama’s trade agenda, and was able to assemble majorities for fast-track legislation earlier this year. To pass the final deal, he simply needs to convince those same members of Congress - some of whom took a substantial political risk to back the fast-track bill - to vote with him again.

Source: Vox


Latest News: Historic Pacific Trade Deal Faces Skeptics in Congress
Twelve Pacific Rim countries on Monday reached the most ambitious trade pact in a generation, aiming to liberalize commerce in 40 percent of the world’s economy in a deal that faces skepticism from U.S. lawmakers.

The Trans-Pacific Partnership (TPP) pact struck in Atlanta after marathon talks could reshape industries, change the cost of products from cheese to cancer treatments and have repercussions for drug companies and automakers.

Tired negotiators worked round the clock over the weekend to settle tough issues such as monopoly rights for new biotech drugs. New Zealand’s demand for greater access for its dairy exports was only settled at 5 a.m. EDT on Monday.

If approved, the TPP pact would cut trade barriers and set common standards for a region stretching from Vietnam to Canada. It would also furnish a legacy-shaping victory for U.S. President Barack Obama, who will further promote the agreement on Tuesday in remarks to business leaders in Washington.

The Obama administration hopes the pact will help the United States increase its influence in East Asia and help counter the rise of China, which is not one of the TPP nations.

Lawmakers in the United States and other TPP countries must approve the deal. Five years in the making, it would reduce or eliminate tariffs on almost 18,000 categories of goods.

Initial reaction from U.S. Congress members, including Democrats and Republicans, ranged from cautious to skeptical.

Source: Reuters

Related: Nike, Obama and the Trans Pacific Partnership Fiasco

Article Topics

Amber Road News & Resources

Logistics Platforms: Ways Companies Can Win In the Digital Era
Ethical Sourcing – The Business Imperative (and Advantage)
How Rules of Origin Really Do Make a Difference for Sourcing Practices
E2open’s acquisition of Amber Road is a done deal
E2open Completes Acquisition of Amber Road
Bridging the Data Gap Between Sourcing and Logistics
Medical Technologies Company Remedies Complex Compliance Operations
More Amber Road

Latest in Supply Chain

Moody’s: Carbon Offsets Open Supply Chains Up to Financial, Reputational Risks
Shippers Focus on Yield Management as Rates Continue to Rise
ASCM Releasees Top 10 Supply Chain Trends for 2024
Suppliers Could Take the Biggest Hit from Auto Union Strike
5 Tips to Help Your Supply Chain Navigate Panama Canal Restrictions
Logility Acquires Generative AI Supply Chain Planning Firm Garvis
National Retail Federation Seeks to ‘Close the Loop,’ Acquires Reverse Logistics Association
More Supply Chain

About the Author

Patrick Burnson's avatar
Patrick Burnson
Mr. Burnson is a widely-published writer and editor specializing in international trade, global logistics, and supply chain management. He is based in San Francisco, where he provides a Pacific Rim perspective on industry trends and forecasts.
Follow Logistics Management on FaceBook

Amber Road

Amber Road, now part of E2open | Amber Road provides a single, on-demand platform that automates and streamlines global trade. By helping organizations to comply with country-specific trade regulations, as well as plan, execute and track global shipments, Amber Road enables goods to flow unimpeded across international borders in the most efficient, compliant and profitable way.

View Amber Road company profile


Featured Downloads

Resource Management System (RMS): How to Effectively Leverage Your Assets
Resource Management System (RMS): How to Effectively Leverage Your Assets
This guide provides an in-depth analysis of the potential of various resources available in a warehouse and how they can be utilized...
Sustainable Supply Chain Insights From PITT OHIO
Sustainable Supply Chain Insights From PITT OHIO
A whitepaper on supply chain insights gleaned at the LEED-certified gold Cleveland transportation and sustainability summit.

20 Warehouse & Distribution Center Best Practices for Your Supply Chain
20 Warehouse & Distribution Center Best Practices for Your Supply Chain
In this guide, we picked the brains of our supply chain engineers to find ways to improve warehouse and distribution center efficiency...
SOLOCHAIN WMS plus a Guide to Warehouse Management Systems
SOLOCHAIN WMS plus a Guide to Warehouse Management Systems
In these 2 'papers' Solochain WMS, we detail Manufacturing Execution System capabilities and Generix's portfolio of SCM solutions to manage all distribution logistics,...
Supply Chain Outlook: What to Expect Near-Future
Supply Chain Outlook: What to Expect Near-Future
An investigation into how supply chains have changed, where they are heading, and how you can prepare.